CSL Shares Slide 5% to A$171 Ahead of FY26 Half-Year Results on Earnings Risk

CSL Ltd shares fell 5% in early trade to A$171.39, extending a multi‑year drawdown of 39% from early 2025 highs as traders position for half‑year FY26 earnings. The A$150B plasma and vaccine group faces concerns over potential revenue and EPS shortfalls, weaker US flu vaccine demand and reimbursement issues for new immunoglobulin products, while options and volume data point to expectations of further downside.